Lexicon Pharmaceuticals (LXRX) Intangibles (2010 - 2020)

Lexicon Pharmaceuticals (LXRX) has 11 years of Intangibles data on file, last reported at $18.8 million in Q2 2020.

• On a quarterly basis, Intangibles fell 61.75% year-over-year to $18.8 million in Q2 2020; TTM through Jun 2020 was $18.8 million, a 61.75% decrease from a year earlier, with the FY2019 full-year figure at $19.7 million, down 60.66% from the prior year.
• Intangibles for Q2 2020 stood at $18.8 million, down from $19.3 million in the prior quarter.
• Over the last five years, Intangibles for LXRX reached as high as $53.4 million in Q1 2016 and fell as low as $18.8 million in Q2 2020.
• Historically, Intangibles has averaged $43.1 million across 5 years, with a median of $50.8 million in 2018.
• Across the five-year window, Intangibles jumped 108.28% in 2018 and tumbled 61.75% in 2020, its largest moves.
• Year by year, Intangibles stood at $53.4 million in 2016, then slipped by 2.76% to $51.9 million in 2017, then slipped by 3.4% to $50.1 million in 2018, then plunged by 60.66% to $19.7 million in 2019, then fell by 4.48% to $18.8 million in 2020.
• Per Business Quant data, the three most recent Intangibles figures were $18.8 million in Q2 2020, $19.3 million in Q1 2020, and $19.7 million in Q4 2019.